Lonza Group strategy in focus, shares lag key health care peers
22.06.2026 - 15:52:31 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 15:51.
Lonza Group (CH0013841017) sits firmly in the global league of pharmaceutical contract manufacturers, with its primary listing on the SIX Swiss Exchange anchoring it in the European health care universe. On this Saturday, investors are again weighing the group’s long-term strategy and margin ambitions in a sector dominated by peers such as Thermo Fisher Scientific and Sartorius.
What recent data say about Lonza
On the Swiss market, Lonza shares recently changed hands around 498.70 Swiss francs, with MarketScreener citing a previous close at that level and an average analyst target price of 663.52 Swiss francs. That implies a marked valuation gap versus consensus expectations, even after a year-on-year share-price decline in the high single digits.
Wallstreet-online reports a market capitalization of roughly 38.2 billion euros for Lonza, with the stock about 16 percent below its 52-week high and around 7.6 percent above its 52-week low. Over the past twelve months the performance is negative, with the site pointing to a roughly 9.6 percent drop, underlining that investors are still demanding proof that the current strategy will translate into renewed earnings momentum.
How analysts frame the stock
According to MarketScreener’s compilation, Lonza is covered by a broad group of European and international banks and brokers that track the stock as part of the life-sciences tools and CDMO segment, with the consensus target mentioned at 663.52 Swiss francs. This positions Lonza alongside global peers like Thermo Fisher Scientific and Catalent in a market where capacity utilization, contract quality and regulatory reliability drive analyst models.
The same MarketScreener snapshot shows that despite the recent weaker share performance, the analyst community still embeds mid-term growth and margin improvement in its valuation framework. For long-only funds benchmarked against indices such as the SMI or broader European health care benchmarks, Lonza’s relative underperformance against some peers keeps the stock in focus when models are updated around earnings seasons.
Background and price data on Lonza Group
Price charts, consensus estimates and corporate disclosures help investors to place the Lonza Group shares in the wider European health care context.
How Lonza earns its money
Lonza’s core business is contract development and manufacturing for the pharmaceutical and biotechnology industries, covering both biologics and small molecules. The group runs a global network of sites that handle cell and gene therapies, large-molecule biologics and highly potent active ingredients, typically under multi-year contracts with big pharma and biotech customers.
Where the shares trade now
Lonza Group shares (CH0013841017) most recently traded around 498.70 Swiss francs on the SIX Swiss Exchange, according to MarketScreener, with a market capitalization near 38.2 billion euros and the stock currently about 16 percent below its 52-week high.
Key data on the Lonza Group shares
- Company: Lonza Group AG
- ISIN: CH0013841017
- WKN: 928619
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-22, 15:30): 498.70 CHF
- Market cap: 38.2 billion EUR (as of 2026-06-22)
- Sector / industry: Health Care - Life Sciences Tools & Services / CDMO
- Index membership: SLI / SPI
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance.
